Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
June 04 2014 - 8:30AM
Marketwired
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan
Drug Status, Funding and Much More in Interview
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc.
(OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald
Crabtree addressed a number of topics associated with the company's
pancreatic cancer treatment in an interview with Stock Market Media
Group, a research and content development investment relations
firm, while the two were attending the American Society of Clinical
Oncology (ASCO) conference in Chicago from Friday May 30 to Tuesday
June 3.
Listen to the interview at:
www.stockmarketmediagroup.com/media
In the interview, both the CEO and COO discussed when the
company expects to begin its upcoming Phase 2b clinical trial in
advanced pancreatic cancer with Clinical Network Services (CNS) and
the company's preclinical studies treating the symptoms associated
with pancreatic cancer to be conducted by Translational Drug
Development (TD2).
Nuvilex's shareholders should draw great confidence from the
interview when they learn where the idea was born to conduct
preclinical and clinical trials on symptoms associated with
pancreatic cancer, and from a CEO who's on a mission to bring a
better treatment to patients suffering from the deadly cancer after
his own father died of the disease.
The company's executives also talked about obtaining Orphan Drug
Status for its pancreatic cancer treatment that uses the
Cell-in-a-Box® technology combined with the anticancer drug
ifosfamide, the new $50 million banking agreement with Chardan
Capital Markets, and much more related to Nuvilex's efforts to get
its pancreatic cancer treatment to market.
Listen to the interview at:
www.stockmarketmediagroup.com/media
About Stock Market Media Group SMMG is a Research and Content
Development IR firm offering a platform for corporate stories to
unfold in the media with Reports, Interviews and Articles. SMMG is
compensated for Nuvilex content by a third party who reserves the
right to buy, sell or remain neutral on securities after the
publication of this article. SMMG has received total compensation
of $93,960 for content related to Nuvilex. Additionally, a
principal at SMMG currently owns 200,000 total shares of Nuvilex
issued by the company through a consulting agreement which has
since ended for work unrelated to content development. All shares
have been held for the requisite period under Rule 144 as of April
30, 2014, and are eligible to be sold immediately without further
notice. For more information: www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact